Department of War Pharmacy Uniform Formulary Blanket Purchase Agreement / Uniform Formulary Additional Discount Program
Solicitation from Department of Defense.
Data as of Oct 24, 2026. Sources: SAM.gov and Grants.gov. Snapshot govcon-directory-20261024T104923Z-2151694.
This product uses the Grants.gov API but is not endorsed or certified by the U.S. Department of Health and Human Services. Counts and totals are computed by DSE from public SAM.gov and Grants.gov notices. Text from Grants.gov may be shortened or have contact details removed. The original notice on Grants.gov is the authoritative version.
Closing in 2 days
Notice details
- Agency
- Department of Defense
- Sub-tier agency
- DEFENSE HEALTH AGENCY (DHA)
- Notice type
- Solicitation
- Solicitation number
- HT9402-26-Q-9404
- Product/service code
- 6505
- Place of performance
- San Antonio, Texas
- Posted
- Oct 9, 2026
- Response deadline
- Oct 26, 2026
- Source
- SAM.gov
Description
The Department of War (DoW) is required by law (10 U.S.C. � 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoW Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoW Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ. P&T COMMITTEE MEETING: The following November 2026 newly approved drugs will be reviewed: a. Adquey - Atopic - Subclass: Topical Agents b. Armlupeg - White Blood Cell Stimulants - Subclass: Pegfilgrastims c. Beqalzi - Oncological Agents - Non-BTKI for Chronic Lymphocytic Leukemia-Small Lymphocytic
Summarized from the official notice. The description is shortened; read the full text on the official notice.
Official notice
Requirements and amendments are controlled by the official notice.
DSE verdict
The DSE fit verdict for this notice is available to DSE GovCon subscribers. It is not published on this page.
See DSE GovCon plans →Similar open notices
- Methylphenidate ERClosing in 13 days
- Epinephrine InjectorClosing in 23 days
- Morphine Sulfate SolutionOpen, no deadline stated
- Bicalutamide TabletsOpen, no deadline stated
- Dapagliflozin TabletsOpen, no deadline stated
Get free alerts
Email alerts for notices like this one are free on DSE GovCon Intelligence.
Set up free alerts →Frequently asked questions
When is the response deadline?
The published deadline is Oct 26, 2026. That is 2 days after the data date.
What NAICS code applies?
NAICS 325412, Pharmaceutical Preparation Manufacturing.
Which agency issued this notice?
Department of Defense.
Where is the official notice?
The link under Official notice opens the source listing.